Guggenheim cuts Universal Health Services price target to $201

Guggenheim lowered its price target for Universal Health Services (UHS) to $201 from $209 while keeping a Buy rating. The revision follows a weak third‑quarter 2026 EBITDA result and slower ramp‑up at new facilities. UHS reported third‑quarter adjusted EPS of $5.22 and revenue of $4.73 billion, both slightly above estimates. The stock was trading around $172.18, down about 8.5% over the week.

The reduced target implies less upside for investors and may weigh on the share price, as the analyst notes weaker profit trends and a cautious 2027 outlook.

Sources